↓ Skip to main content

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives

Overview of attention for article published in Cardiovascular Diabetology, February 2019
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#15 of 900)
  • High Attention Score compared to outputs of the same age (93rd percentile)

Mentioned by

twitter
71 tweeters

Citations

dimensions_citation
24 Dimensions

Readers on

mendeley
61 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
Published in
Cardiovascular Diabetology, February 2019
DOI 10.1186/s12933-019-0828-y
Pubmed ID
Authors

Chiara Maria Assunta Cefalo, Francesca Cinti, Simona Moffa, Flavia Impronta, Gian Pio Sorice, Teresa Mezza, Alfredo Pontecorvi, Andrea Giaccari

Twitter Demographics

The data shown below were collected from the profiles of 71 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 61 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 18%
Student > Bachelor 8 13%
Student > Master 7 11%
Student > Ph. D. Student 7 11%
Other 6 10%
Other 11 18%
Unknown 11 18%
Readers by discipline Count As %
Medicine and Dentistry 29 48%
Pharmacology, Toxicology and Pharmaceutical Science 7 11%
Biochemistry, Genetics and Molecular Biology 5 8%
Agricultural and Biological Sciences 2 3%
Nursing and Health Professions 2 3%
Other 3 5%
Unknown 13 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 41. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 September 2019.
All research outputs
#542,427
of 15,870,408 outputs
Outputs from Cardiovascular Diabetology
#15
of 900 outputs
Outputs of similar age
#16,732
of 269,559 outputs
Outputs of similar age from Cardiovascular Diabetology
#1
of 1 outputs
Altmetric has tracked 15,870,408 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 900 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.3. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 269,559 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them